Aspergillosis of the Lung
Presenting as Hemoptysis

R. L. Gupta, N. Saxena, Sharad Kumar, Monika Mahajan

Abstract
Among mycotic diseases of the lung, pulmonary aspergillosis caused by aspergilloma fumigatus is the one encountered most frequently. An unusual case with a cystic lesion in the lung which turned out to be an aspergilloma is presented here.

Key Words
Aspergilloma, Haemoptysis, Fungus infections.

Introduction
Pulmonary Aspergillosis is commonly present in patients who are immunosuppressed or have chronic lung diseases. Majority of these patients present with hemoptysis. Although a routine chest radiograph may suggest the diagnosis of aspergillosis, CT scan is the best investigation to confirm it and plan the extent of surgery. Operative resection is the best modality of treatment as it offers permanent cure and avoids any need for antifungal therapy.

Case Report
A 30 year old lady presented with complaints of hemoptysis for last 12 years. This was occasional i.e. once in 3-4 months. She had no other associated complaints like chest pain, breathlessness. There was no history of fever, nausea, vomiting, loss of appetite or loss of weight. She had past history of pulmonary Koch's 12 years ago and had received a full course of antitubercular therapy.

She was investigated for the cause of hemoptysis. Routine blood investigations like Hemogram, blood urea, sugar, liver function tests were within normal limits except a raised ESR (60 mm in 1st hr.). Sputum for AFB was negative. Chest x-ray revealed a cavity in the right perihilar region with an eccentric soft density mass in it suggesting a possibility of hydatid cyst or a fungal infection.

Bronchoscopy did not reveal any growth but fresh bleeding was spotted from the opening of superior segment of right lower lobe. Bronchial aspirate and sputum were negative for AFB, malignant cells and
Aspergillosis is a fungal infection usually caused by Aspergillus fumigatus. Two forms of aspergillosis are recognised—primary and secondary. Secondary occurs in damaged lungs or in lungs of host with impaired defence mechanisms due to AIDS, malignant disease such as leukaemia or lymphoma or to therapeutic agents such as steroids, anti-metabolites, cytotoxic drugs, antibiotics or other drugs causing bone marrow depression (1,2,3). More frequently, it occurs in chronic lung disease as a saprophytic coloniser of pre-existing cavities e.g. caused by tuberculosis, bronchiectasis etc. (4,5). Aspergillomas commonly grow in tuberculous cavities. A British Tuberculosis Association report (4) states that aspergillomas occur in 15% of open negative cavities larger than 2.5 cm with the highest incidence in cavities of seven to eleven years duration. North American series have less incidence of tuberculosis (33%) as reported by Faulkner and Colleagues (6) and there, aspergillosis is seen most commonly in association with histoplasmosis (19%), sarcoidosis and ankylosing spondylitis (7). Pleural aspergillomas most often develop in a residual pleural space after operation (or formerly after collapse therapy).
for tuberculosis) and is favoured by a bronchopleural fistula (8).

The predominant symptoms of aspergillosis are hemoptysis, bronchorrhoea, fever and weight loss. Hemoptysis occurs in 50 to 80% of patients (1,9). It can be so severe as to be fatal and therefore aspergillomas are best treated surgically (10).

Diagnosis is based on repeated isolation of the fungus from the sputum (11), transbronchial lavage or biopsy, chest x-ray, CT scan, complement fixation test and aspergillus skin test. Chest x-ray shows an air crescent sign that is a cavity with an eccentric shadow of a fungus ball (mycetoma) in it (12). Similar appearance is seen on a CT scan which is good for localisation and determining the surgical approach (13). Differential diagnosis includes intracavitary blood clots, liquefying pulmonary infection and hydatid cyst (14).

Treatment of pulmonary or pleural aspergilloma is primarily surgical. The surgical mortality is low (less than 7%) as reported by Kilman (15), potential for cure is excellent and the danger of antifungal chemotherapy is obviated. Surgery is recommended when the following criteria are satisfied (16):

1. Aspergilloma and underlying lung disease are not widespread.
2. Patient has recurrent episodes of hemoptysis or chronic production of purulent sputum.
3. Patients is in good health.

Mortality rates are high (38-44%) when operating on symptomatic patients specially when functional and nutritional status of the patients are bad (17-19). However, operation is advised because symptomatic manifestations may become life threatening. A segmental or lobar resection may be attempted only if the lesions are confined to a single lobe and if the functional and nutritional status of the patient are consistent with a major surgical procedure. In all other cases a pleuropneumonectomy for removal of the mycetoma followed by immediate thoracoplasty is recommended (20-21). The most appropriate procedure recommended for aspergillus empyema is a generous thoracoplasty (20).

In asymptomatic patients mortality rates are low (7%) as reported by Daly et. al. (17). Such patients should undergo operation on principle. The ideal procedure is segmental or lobar resection (20). Lobectomy is the preferred procedure. Pneumonectomy has been done for widespread disease (1). The extent of resection of intrapulmonary aspergilloma depends on the severity of the underlying lung pathology as well as the aspergilloma itself (22). Because of the saprophytic nature of the organism, resection should be limited so as not to decrease lung function but since the organism can be invasive, a segmental or wedge resection can sometimes be dangerous (16).

There is no alternative to operative treatment. Systemic administration of amphotericin-B or itraconazole (23) is currently beneficial only for invasive aspergillosis. It has a questionable action on the mycetoma. Direct intracavitary instillation of antifungal agents such as amphotericin B, sodium iodide should be resorted to as primary therapy in patients whose general medical status or poor pulmonary reserve makes the operative risk prohibitive (24).

References